

UNITED STATES DISTRICT COURT  
DISTRICT OF RHODE ISLAND

RICHARD MEDOFF, Individually and On	)	No. 1:09-cv-00554-JNL-PAS
Behalf Of All Others Similarly Situated,	)	
	)	<u>CLASS ACTION</u>
Plaintiff,	)	
	)	
vs.	)	
	)	
CVS CAREMARK CORPORATION, et al.,	)	
	)	
Defendants.	)	
	)	
_____	)	

**DECLARATION OF ADAM D. WALTER ON BEHALF OF A.B. DATA, LTD.  
REGARDING MAILING OF NOTICE TO POTENTIAL CLASS MEMBERS AND  
PUBLICATION OF SUMMARY NOTICE**

I, Adam D. Walter, declare as follows:

1. I am a Senior Project Manager of A.B. Data, Ltd.’s Class Action Administration Division (“A.B. Data”), whose Corporate Office is located in Milwaukee, Wisconsin. Pursuant to the Order Certifying Class, Preliminarily Approving Settlement, and Providing for Notice (the “Preliminary Approval Order”), A.B. Data was authorized to act as the Claims Administrator in connection with the Settlement in the above-captioned action. I am over 21 years of age and am not a party to this action. I have personal knowledge of the facts set forth herein and, if called as a witness, could and would testify competently thereto.

**MAILING OF THE NOTICE AND PROOF OF CLAIM**

2. Pursuant to the Preliminary Approval Order, A.B. Data mailed the Notice of Proposed Settlement of Class Action (the “Notice”) and the Proof of Claim and Release form (the “Proof of Claim” and collectively with the Notice, the “Notice Packet”) to potential Class Members. A copy of the Notice Packet is attached hereto as Exhibit A.

3. On November 9, 2015, A.B. Data received 8,545 names and addresses of record holders from Lead Counsel. Once received, the data was electronically processed by A.B. Data to ensure adequate address formatting and the elimination of duplicate names and addresses, which resulted in 7,034 distinct records for mailing. A.B. Data also standardized and updated the mailing list addresses using NCOALink<sup>®</sup>, a national database of address changes that is compiled by the United States Postal Service.

4. As in most class actions of this nature, the majority of potential Class Members are beneficial purchasers whose securities are held in “street name” –*i.e.*, the securities are purchased by brokerage firms, banks, institutions and other third-party nominees in the name of the nominee, on behalf of the beneficial purchasers. A.B. Data maintains a proprietary database with names and addresses of the largest and most common banks, brokers, and other nominees. On November 20, 2015, A.B. Data caused Notice Packets to be mailed to the 5,295 mailing records contained in the A.B. Data record holder mailing database.

5. In total, 12,329 Notice Packets were mailed to potential Class Members and their nominees by first-class mail on November 20, 2015.

6. On November 24, 2015, A.B. Data also submitted the Notice to the Depository Trust Company to post on their Legal Notice System, which offers DTC member banks and brokers access to a comprehensive library of notices concerning DTC-eligible securities.

7. With respect to AB Data’s outreach to brokers and nominees, the Notice requested that those who purchased or acquired the common stock of CVS Caremark during the Class Period for the beneficial interest of a person or organization other than themselves, within ten calendar days after receipt of the Notice Packet, either (i) provide to A.B. Data the names and

addresses of such beneficial owners; or (ii) send copies of the Notice Packet to such beneficial owners. *See* Notice on page 8.

8. As of the date of this Declaration, A.B. Data has received an additional 430,169 names and addresses of potential Class Members from individuals or brokerage firms, banks, institutions and other nominees. A.B. Data has also received requests from brokers and other nominee holders for 76,245 Notice Packets, which the brokers and nominees are required to mail to their customers. All such mailing requests have been, and will continue to be, complied with and addressed by A.B. Data in a timely manner.

9. As of the date of this Declaration, 462 Notice Packets were returned by the United States Postal Service to A.B. Data as undeliverable as addressed (“UAA”). Of those returned UAA, 36 had forwarding addresses and were promptly re-mailed to the updated address. The remaining 426 UAAs were processed through LexisNexis to obtain an updated address. Of these, 287 new addresses were obtained and A.B. Data promptly re-mailed to these potential Class Members.

10. As of the date of this Declaration, a total of 519,066 Notice Packets have been mailed to potential Class Members and their nominees.

#### **PUBLICATION OF THE SUMMARY NOTICE**

11. In accordance with Paragraph 7(c) of the Preliminary Approval Order, on December 4, 2015, A.B. Data caused the Summary Notice to be published in *Investor’s Business Daily* and the release of the Summary Notice via *PR Newswire*. Proof of this publication is attached hereto as Exhibits B and C, respectively.

**TELEPHONE HOTLINE**

12. On or about November 20, 2015, a case-specific toll-free phone number, 800-949-0206, was established with an Interactive Voice Response system and live operators. An automated attendant answers all calls initially and presents callers with a series of choices to respond to basic questions. If callers need further help, they have the option to be transferred to a live operator during business hours.

13. From November 20, 2015 through the date of this Declaration, A.B. Data received 132 telephone calls.

**WEBSITE**


14. On or about November 20, 2015, A.B. Data established a case-specific website, [www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com), which includes general information regarding the case and its current status, downloadable copies of the Notice, Proof of Claim, and other court documents, including the Stipulation of Settlement. In addition, the website allows potential Class Members to complete and submit their Proof of Claim online. The settlement website is accessible 24 hours a day, 7 days a week.

**REPORT ON EXCLUSIONS**

15. The Notice informed potential Class Members that requests for exclusion are to be sent to the Claims Administrator, such that they are postmarked no later than January 6, 2016. As of the date of this Declaration, A.B. Data has received no requests for exclusion.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed this 11<sup>th</sup> day of December, 2015.

  
Adam D. Walter

CERTIFICATE OF SERVICE

I, Barry J. Kusnitz, hereby certify that on December 15, 2015, I caused a true and correct copy of the attached:

DECLARATION OF ADAM D. WALTER ON BEHALF OF A.B. DATA, LTD. REGARDING MAILING OF NOTICE TO POTENTIAL CLASS MEMBERS AND PUBLICATION OF SUMMARY NOTICE

to be electronically filed with the Clerk of the Court using the CM/ECF system, which will send notification of such public filing to all counsel registered to receive such notice.

*/s/ Barry J. Kusnitz*

---

BARRY J. KUSINITZ

## Mailing Information for a Case 1:09-cv-00554-JNL-PAS Medoff v. CVS Caremark Corporation et al

### Electronic Mail Notice List

The following are those who are currently on the list to receive e-mail notices for this case.

- **Christopher M. Barrett**  
cbarrett@rgrdlaw.com
- **David K. Baumgarten**  
dbaumgarten@wc.com
- **Matthew H. Blumenstein**  
mblumenstein@wc.com
- **Erin W. Boardman**  
eboardman@rgrdlaw.com
- **Guillaume Buell**  
gbuell@labaton.com
- **Mitchell R. Edwards**  
medwards@hinckleyallen.com,dfalcoa@hinckleyallen.com
- **Steven M. Farina**  
sfarina@wc.com
- **Christine M. Fox**  
cfox@labaton.com
- **Jonathan Gardner**  
jgardner@labaton.com
- **Jonah H. Goldstein**  
jgoldstein@rgrdlaw.com
- **William R. Grimm**  
wgrimm@hinckleyallen.com,mconnolly@hinckleyallen.com,achristiansen@hinckleyallen.com
- **Deborah R. Gross**  
DGross@kcr-law.com,JHannigan@kcr-law.com
- **Serena P. Hallowell**  
shallowell@labaton.com,cvillegas@labaton.com,egottlieb@labaton.com,acoquin@labaton.com,agreenbaum@labaton.com,electroniccasefiling@labaton.com,cfox@lab  
lee@labaton.com,gbuell@labaton.com,lmehringner@labaton.com,fimalonzo@labaton.com,acarpio@labaton.com,ewierzbowski@labaton.com
- **Bailie L. Heikkinen**  
bheikkinen@rgrdlaw.com
- **Margaret A. Keeley**  
mkeeley@wc.com
- **Barry J. Kusnitz**  
bkusnitz@bdglawyers.com
- **Leslie C. Mahaffey**  
lmahaffey@wc.com
- **Robert J. Robbins**  
rrobbins@rgrdlaw.com,e\_file\_sd@rgrdlaw.com,e\_file\_fl@rgrdlaw.com
- **David A. Rosenfeld**  
drosenfeld@rgrdlaw.com,e\_file\_sd@rgrdlaw.com
- **Robert M. Rothman**  
rrothman@rgrdlaw.com,e\_file\_ny@rgrdlaw.com,cbarrett@rgrdlaw.com,e\_file\_sd@rgrdlaw.com
- **Katherine M. Turner**  
kturner@wc.com

### Manual Notice List

The following is the list of attorneys who are **not** on the list to receive e-mail notices for this case (who therefore require manual noticing). You may wish to use your mouse to select and copy this list into your word processing program in order to create notices or labels for these recipients.

- (No manual recipients)

# EXHIBIT A



RICHARD MEDOFF, Individually and On Behalf Of )	No. 1:09-cv-00554-JNL-PAS
All Others Similarly Situated, )	
	) <u>CLASS ACTION</u>
Plaintiff, )	
	) NOTICE OF PROPOSED SETTLEMENT OF CLASS
vs. )	ACTION
	)
CVS CAREMARK CORPORATION, et al., )	
	)
Defendants. )	
	)

**TO: ALL PERSONS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE COMMON STOCK OF CVS CAREMARK CORPORATION (“CVS CAREMARK”) (N/K/A CVS HEALTH CORPORATION) BETWEEN OCTOBER 30, 2008 AND NOVEMBER 4, 2009, INCLUSIVE, AND WERE DAMAGED THEREBY**

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THIS LITIGATION. PLEASE NOTE THAT IF YOU ARE A CLASS MEMBER, YOU MAY BE ENTITLED TO SHARE IN THE PROCEEDS OF THE SETTLEMENT DESCRIBED IN THIS NOTICE. TO CLAIM YOUR SHARE OF THIS FUND, YOU MUST SUBMIT A VALID PROOF OF CLAIM AND RELEASE FORM (“PROOF OF CLAIM”) **POSTMARKED OR SUBMITTED ONLINE ON OR BEFORE MARCH 23, 2016.**

This Notice of Proposed Settlement of Class Action (“Notice”) has been sent to you pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Rhode Island (the “Court”). The purpose of this Notice is to inform you of the proposed Settlement of the case entitled *Richard Medoff v. CVS Caremark Corporation, et al.*, No. 1:09-cv-00554-JNL-PAS (D.R.I.) (the “Litigation”) and of the hearing (the “Settlement Hearing”) to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement as set forth in the Stipulation of Settlement between Co-Lead Plaintiffs and Defendants, dated as of August 24, 2015 (the “Stipulation”), on file with the Court.

This Notice is not intended to be, and should not be construed as, an expression of any opinion by the Court with respect to the truth of the allegations in the Litigation as to any of the Defendants or the merits of the claims or defenses asserted by or against Defendants. This Notice is solely to advise you of the proposed Settlement of the Litigation and of your rights in connection therewith.

**I. STATEMENT OF CLASS RECOVERY**

The proposed Settlement will result in the creation of a cash settlement fund in the principal amount of Forty-Eight Million Dollars (\$48,000,000.00), plus any interest that may accrue thereon (the “Settlement Fund”).

The Settlement Fund, subject to deduction for, among other things, costs of class notice and administration, certain taxes and tax related expenses, and for attorneys’ fees and expenses as approved by the Court, will be available for distribution to Class Members. Your recovery from this fund will depend on a number of variables, including the number of shares of CVS Caremark common stock you purchased or acquired between October 30, 2008 and November 4, 2009, inclusive (the “Class Period”), and the timing of your purchases, acquisitions, and any sales. In the unlikely event that 100% of the eligible common stock of CVS Caremark purchased or acquired by Class Members and entitled to a distribution under the Plan of Allocation described below participate in the Settlement, the estimated average distribution per share of CVS Caremark common stock will be approximately \$0.25 before deduction of Court-approved fees and expenses. Historically, actual claim rates are lower than 100%, resulting in higher per share distributions.

**II. STATEMENT OF POTENTIAL OUTCOME**

Co-Lead Plaintiffs and Defendants do not agree on the average amount of damages per share, if any, that would have been recoverable if Co-Lead Plaintiffs were to have prevailed on each claim alleged. Defendants deny that they are liable in any respect or that Co-Lead Plaintiffs or the Class suffered any injury. The issues on which the parties disagree are many, but include: (1) whether Defendants engaged in conduct that would give rise to any liability to the Class under the federal securities laws, or any other laws; (2) whether Defendants have valid defenses to any such claims of liability; (3) the appropriate economic model for determining the amount by which the price of CVS Caremark common stock was allegedly artificially inflated (if at all) during the Class Period; (4) the amount by which the price of CVS Caremark common stock was allegedly artificially inflated (if at all) during the Class Period; (5) the effect of various market forces on the price of CVS Caremark common stock at various times during the Class Period; (6) the extent to which external factors influenced the price of CVS Caremark common stock at various times during the Class Period; (7) the extent to which the various matters that Co-Lead Plaintiffs alleged were materially false or misleading influenced (if at all) the price of CVS Caremark common stock at various times during the Class Period; and (8) the extent to which the various allegedly adverse material facts that Co-Lead Plaintiffs alleged were omitted influenced (if at all) the price of CVS Caremark common stock at various times during the Class Period.

**III. REASONS FOR SETTLEMENT**

Co-Lead Plaintiffs believe that the proposed Settlement is a good recovery and is in the best interests of the Class. Because of the risks associated with continuing to litigate and proceeding to trial, there was a danger that the Class would not have prevailed on any of its claims, in

Case 1:09-cv-00554-JNL-PAS Document 135-1 Filed 12/15/15 Page 3 of 15 PageID #: 3837

which case the Class would receive nothing. Also, the amount of damages recoverable by the Class was and is challenged by Defendants. Recoverable damages in this case are limited to losses caused by conduct actionable under applicable law and, had the litigation gone to trial, Defendants would have asserted that any losses of Class Members were caused by non-actionable market, industry, or general economic factors. Defendants also would have asserted that throughout the Class Period the uncertainties and risks associated with the purchase of CVS Caremark common stock were fully and adequately disclosed. The proposed Settlement provides a certain benefit to Class Members, and will avoid the years of delay that would likely occur in the event of a contested trial and appeals.

#### **IV. STATEMENT OF ATTORNEYS' FEES AND EXPENSES SOUGHT**

Lead Counsel have not received any payment for their services in conducting this Litigation on behalf of the Co-Lead Plaintiffs and Members of the Class, nor have they been paid for their litigation expenses. If the Settlement is approved by the Court, Lead Counsel will apply to the Court for attorneys' fees of up to 30% of the Settlement Amount and expenses not to exceed \$1,050,000.00, plus interest thereon, to be paid from the Settlement Fund. If the amounts requested are approved by the Court, the average cost per share of CVS Caremark common stock will be \$0.08. In addition, each of the three Co-Lead Plaintiffs may seek up to \$20,000 in expenses incurred in representing the Class.

#### **V. IDENTIFICATION OF ATTORNEYS' REPRESENTATIVES**

For further information regarding this Settlement, you may contact representatives of Lead Counsel: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, Telephone: 800/449-4900, or Nicole M. Zeiss, Settlement Counsel, Labaton Sucharow LLP, 140 Broadway, 34<sup>th</sup> Floor, New York, NY, 10005, Telephone: 888/219-6877.

#### **VI. NOTICE OF HEARING ON PROPOSED SETTLEMENT**

A hearing (the Settlement Hearing) will be held on **January 19, 2016, at 10:00 a.m.**, before the Honorable Joseph N. Laplante, United States District Judge, at the United States District Court for the District of New Hampshire, 55 Pleasant Street, Courtroom 2, Concord, New Hampshire 03301-3941. The purpose of the Settlement Hearing will be to determine: (1) whether the proposed Settlement, as set forth in the Stipulation, consisting of Forty-Eight Million Dollars (\$48,000,000.00) in cash, should be approved as fair, reasonable, and adequate to the Members of the Class; (2) whether the proposed plan to distribute the Settlement proceeds (the "Plan of Allocation") is fair, reasonable, and adequate; (3) whether the application by Lead Counsel for an award of attorneys' fees and expenses and the expenses of Co-Lead Plaintiffs should be approved; and (4) whether the Judgment, in the form attached to the Stipulation, should be entered. The Court may adjourn the Settlement Hearing from time to time and without further notice to the Class.

#### **VII. DEFINITIONS USED IN THIS NOTICE**

As used in this Notice, the following terms have the meanings specified below. Any capitalized terms not specifically defined in this Notice shall have the meanings set forth in the Stipulation. In the event of any inconsistency between any definition set forth below or elsewhere in this Notice and any definition set forth in the Stipulation, the definition set forth in the Stipulation shall control.

1. "Authorized Claimant" means any Class Member whose claim for recovery has been allowed pursuant to the terms of the Stipulation.
2. "Claims Administrator" means the firm of A.B. Data.
3. "Class" means all persons and entities who purchased, or otherwise acquired, CVS Caremark common stock between October 30, 2008 and November 4, 2009, inclusive, and were damaged thereby. Excluded from the Class are Defendants; the other officers and directors of CVS Caremark; members of the immediate families of any excluded person; the legal representatives, heirs, successors, or assigns of any excluded person or entity; and any entity controlled by, or in which Defendants have or had a controlling interest. Also excluded are those Persons who timely and validly request exclusion from the Class pursuant to the instructions contained in this Notice.
4. "Class Member" or "Member of the Class" mean a Person who falls within the definition of the Class as set forth above.
5. "Class Period" means the period from October 30, 2008 through November 4, 2009, inclusive.
6. "Co-Lead Plaintiffs" means City of Brockton Retirement System, Plymouth County Retirement System, and Norfolk County Retirement System.
7. "CVS Caremark" means CVS Caremark Corporation, which is now named CVS Health Corporation.
8. "Defendants" means CVS Caremark and the Individual Defendants.
9. "Effective Date," or the date upon which this Settlement becomes "effective," means three (3) business days after the date by which all of the events and conditions specified in paragraph 7.1 of the Stipulation have been met and have occurred.
10. "Escrow Agent" means the law firms of Robbins Geller Rudman & Dowd LLP and Labaton Sucharow LLP, or their respective successors.
11. "Final" means when the last of the following with respect to the Judgment approving the Stipulation, substantially in the form of Exhibit B attached to the Stipulation, shall occur: (i) the expiration of the time to file a motion to alter or amend the Judgment under Federal Rule of Civil Procedure 59(e) without any such motion having been filed; (ii) the time in which to appeal the Judgment has passed without any appeal having been taken; and (iii) if a motion to alter or amend is filed or if an appeal is taken, immediately after the determination of that motion or appeal so that it is no longer subject to any further judicial review or appeal whatsoever, whether by reason of affirmance by a court of last resort, lapse of time, voluntary dismissal of the appeal or otherwise in such a manner as to permit the consummation of the Settlement, substantially in accordance with the terms and conditions of the Stipulation. For purposes of this paragraph, an "appeal" shall include any petition for a writ of certiorari or other writ that may be filed in connection with approval or disapproval of this Settlement. Any appeal or proceeding seeking subsequent judicial review pertaining solely to Co-Lead Plaintiffs' counsel's attorneys' fees and expenses, payments to Co-Lead Plaintiffs for

12. "Individual Defendants" means Thomas M. Ryan, David B. Rickard, and Howard A. McLure.
13. "Judgment" means the Final Judgment and Order of Dismissal with Prejudice to be rendered by the Court, substantially in the form attached as Exhibit B to the Stipulation.
14. "Lead Counsel" means Robbins Geller Rudman & Dowd LLP, Robert M. Rothman, 58 South Service Road, Suite 200, Melville, New York 11747 and Labaton Sucharow LLP, Jonathan Gardner, 140 Broadway, 34th Floor, New York, New York 10005.
15. "Litigation" means the action captioned *Richard Medoff v. CVS Caremark Corporation, et al.*, No. 1:09-cv-00554-JNL-PAS (D.R.I.).
16. "Net Settlement Fund" means the Settlement Fund less: (i) any Court-awarded attorneys' fees, costs, expenses, and interest thereon; (ii) any award to Co-Lead Plaintiffs for their reasonable costs and expenses (including lost wages) pursuant to the Private Securities Litigation Reform Act of 1995 ("PSLRA"); (iii) Notice and Administration Expenses; (iv) Taxes and Tax Expenses; and (v) other Court-approved deductions.
17. "Notice and Administration Expenses" means the reasonable costs and expenses actually incurred in connection with providing notice of the Settlement to the Class by mail, publication and other means, locating Class Members, assisting with the submission of claims, processing Proof of Claim forms, administering the Settlement, and paying escrow fees and costs, if any.
18. "Person" means an individual, corporation, partnership, limited partnership, association, joint stock company, estate, legal representative, trust, unincorporated association, government or any political subdivision or agency thereof, and any business or legal entity and their spouses, heirs, predecessors, successors, representatives, or assignees.
19. "Plan of Allocation" means a plan or formula of allocation of the Net Settlement Fund whereby the Net Settlement Fund shall be distributed to Authorized Claimants. Any Plan of Allocation is not part of the Stipulation and neither Defendants nor their Related Parties shall have any responsibility or liability with respect thereto.
20. "Related Parties" means each of a Defendant's respective present and former parents, subsidiaries, divisions and affiliates and the respective present and former employees, members, partners, principals, officers, directors, attorneys, advisors, accountants, auditors, and insurers of each of them; and the predecessors, successors, estates, heirs, executors, trusts, trustees, administrators, agents, representatives and assigns of each of them, in their capacity as such.
21. "Released Claims" means any and all claims and causes of action of every nature and description, whether known or unknown, whether arising under federal, state, common or foreign law, that arise out of or relate in any way to both: (i) the purchase or acquisition of CVS Caremark common stock during the Class Period, and (ii) the acts, facts, statements, or omissions that were asserted or could have been asserted in the Litigation by Co-Lead Plaintiffs or Members of the Class. "Released Claims" does not include: (i) claims to enforce the Settlement; and (ii) claims in any related derivative action. "Released Claims" includes "Unknown Claims" as defined below.
22. "Released Persons" means each and all of the Defendants and their Related Parties.
23. "Settlement" means the resolution of the Litigation in accordance with the terms and provisions of the Stipulation.
24. "Settlement Amount" means Forty-Eight Million Dollars (\$48,000,000.00) in cash to be paid by wire transfer to the Escrow Agent pursuant to paragraph 2.1 of the Stipulation.
25. "Settlement Fund" means the Settlement Amount plus all interest and accretions thereto.
26. "Settling Parties" means, collectively, Defendants, Co-Lead Plaintiffs, and the Class.
27. "Tax" or "Taxes" mean any and all taxes, fees, levies, duties, tariffs, imposts, and other charges of any kind (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any governmental authority.
28. "Unknown Claims" means any Released Claims or Released Defendants' Claims which any of the Settling Parties or Class Members do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, Co-Lead Plaintiffs, plaintiffs' counsel, or Class Members which, if known by him, her, or it, might have affected his, her, or its settlement with and release, or might have affected his, her, or its decision not to object to this Settlement or release of the Released Persons, Co-Lead Plaintiffs, plaintiffs' counsel, or Class Members. With respect to any and all Released Claims and Released Defendants' Claims, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each of the Settling Parties shall be deemed to have, and by operation of the Judgment shall have, expressly waived the provisions, rights, and benefits of California Civil Code §1542, which provides:

**A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.**

The Settling Parties shall expressly waive and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable or equivalent to California Civil Code §1542. The Settling Parties may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but the Settling Parties shall expressly settle and release and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims and Released Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the

future, including but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and a key element of the Settlement of which this release is a part.

## **VIII. THE LITIGATION**

The initial complaint in this Litigation was filed on November 17, 2009 in the United States District Court for the District of Rhode Island. On March 1, 2010, the Court appointed City of Brockton Retirement System, Plymouth County Retirement System, and Norfolk County Retirement System as lead plaintiffs.

On June 1, 2010, Co-Lead Plaintiffs filed the operative Corrected Consolidated Class Action Complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Complaint"). The named defendants in the Complaint were CVS Caremark and the Individual Defendants. On July 2, 2010, Defendants moved to dismiss the Complaint. On June 18, 2012, the Court granted Defendants' motion to dismiss.

Co-Lead Plaintiffs appealed from the Court's Opinion and Order. By Order dated May 24, 2013, the United States Court of Appeals for the First Circuit vacated the dismissal of the Complaint and remanded the case for further proceedings. Following remand, the parties submitted supplemental briefing on potential grounds for dismissal, not addressed in the Court's June 18, 2012 Order. By Memorandum Order dated December 30, 2013, the Court denied Defendants' motion to dismiss.

On February 7, 2014, Defendants filed an answer denying all material allegations in the Complaint and asserting defenses to the claims.

On February 6, 2015, Co-Lead Plaintiffs filed a motion for class certification, which has been fully briefed and included the submission of expert reports. The motion was pending when the parties agreed to settle.

During the pendency of the Litigation, Co-Lead Plaintiffs and Defendants engaged in extensive discovery. The parties served document demands upon each other and subpoenas upon 60 non-parties, resulting in the production of more than 1.3 million pages of documents. In addition, the parties took 15 depositions.

In the course of the Litigation, the parties engaged the services of the Honorable Layn R. Phillips (Ret.), a retired United States District Judge and a nationally recognized mediator. The parties engaged in an in-person mediation session with Judge Phillips on August 24, 2015. These efforts culminated with the parties agreeing to settle the Litigation for \$48,000,000.00, subject to the negotiation of the terms of a Stipulation of Settlement and approval by the Court.

## **IX. CO-LEAD PLAINTIFFS' CLAIMS AND THE BENEFITS OF SETTLEMENT**

Co-Lead Plaintiffs believe that the claims asserted in the Litigation have merit and that the evidence developed to date supports the claims. However, Co-Lead Plaintiffs and their counsel recognize and acknowledge the expense and length of continued proceedings necessary to prosecute the Litigation against Defendants through trial and through appeals. Co-Lead Plaintiffs and their counsel also have taken into account the uncertain outcome and the risk of any litigation, especially in complex actions such as this Litigation, as well as the difficulties and delays inherent in such litigation. Co-Lead Plaintiffs and their counsel also are mindful of the inherent problems of proof under, and possible defenses to, the securities law violations asserted in the Litigation. Co-Lead Plaintiffs and their counsel believe that the Settlement set forth in the Stipulation confers substantial benefits upon the Class. Based on their evaluation, Co-Lead Plaintiffs and their counsel have determined that the Settlement set forth in the Stipulation is in the best interests of Co-Lead Plaintiffs and the Class.

## **X. DEFENDANTS' DENIALS OF WRONGDOING AND LIABILITY**

Defendants have denied and continue to deny each and all of the claims alleged by Co-Lead Plaintiffs and the Class in the Litigation. Defendants expressly have denied and continue to deny all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Litigation. Defendants also have denied and continue to deny, among other allegations, the allegations that Co-Lead Plaintiffs or the Class have suffered any damages, that the price of CVS Caremark common stock was artificially inflated by reasons of alleged misrepresentations, non-disclosures or otherwise, or that Co-Lead Plaintiffs or the Class were harmed by the conduct alleged in the Litigation or that could have been alleged as part of the Litigation. Defendants believe that the evidence developed to date supports their position that they acted properly at all times and that the Litigation is without merit. In addition, Defendants maintain that they have meritorious defenses to all claims alleged in the Litigation.

Nonetheless, Defendants have concluded that further conduct of the Litigation would be protracted and expensive, and that it is desirable that the Litigation be fully and finally settled in the manner and upon the terms and conditions set forth in the Stipulation. Defendants also have taken into account the uncertainty and risks inherent in any litigation, especially in complex cases such as this Litigation.

## **XI. TERMS OF THE PROPOSED SETTLEMENT**

A Settlement has been reached in the Litigation between Co-Lead Plaintiffs and Defendants, the terms and conditions of which are set forth in the Stipulation and the Exhibits thereto. The following description of the proposed Settlement is only a summary, and reference is made to the text of the Stipulation, on file with the Court and accessible at [www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com), for a full statement of its provisions.

The Settlement Fund consists of Forty-Eight Million Dollars (\$48,000,000.00) in cash, plus any interest earned thereon.

A portion of the Settlement proceeds will be used to pay attorneys' fees and expenses to Lead Counsel and Co-Lead Plaintiffs' expenses, to pay for Notice and Administration Expenses, and to pay Taxes and Tax Expenses. The balance of the Settlement Fund (the Net Settlement Fund) will be distributed, in accordance with the Plan of Allocation described below, to Class Members who submit valid and timely Proofs of Claim.

## **XII. THE RIGHTS OF CLASS MEMBERS**

If you are a Class Member, you may receive the benefit of, and you will be bound by the terms of, the proposed Settlement described in this Notice, upon approval of the proposed Settlement by the Court.

If you are a Class Member, you have the following options:

1. You may submit a Proof of Claim as described below. If you choose this option, you will share in the proceeds of the proposed Settlement if your claim is timely, valid, and entitled to a distribution under the Plan of Allocation described below and if the proposed Settlement is finally approved by the Court; and you will be bound by the Judgment and release to be entered by the Court as described below.
2. If you timely and validly request exclusion from the Class pursuant to Section XV of this Notice and you do nothing further: (a) you are excluded from the Class; (b) you are not entitled to share in the proceeds of the Settlement described herein; (c) you are not bound by any judgment entered in the Litigation; and (d) you are not precluded, by reason of your decision to request exclusion from the Class, from otherwise prosecuting an individual claim, if timely, against Defendants based on the matters complained of in the Litigation.
3. If you do not make a valid and timely request in writing to be excluded from the Class, you will be bound by any and all determinations or judgments in the Litigation in connection with the Settlement entered into or approved by the Court, whether favorable or unfavorable to the Class, and you shall be deemed to have, and by operation of the Judgment shall have, fully released all of the Released Claims against the Released Persons, whether or not you submit a valid Proof of Claim.
4. You may do nothing at all. If you choose this option, you will not share in the proceeds of the Settlement, but you will be bound by any judgment entered by the Court, and you shall be deemed to have, and by operation of the Judgment shall have, fully released all of the Released Claims against the Released Persons.
5. You may object to the Settlement, the Plan of Allocation, the application for attorneys' fees and expenses, and/or the expenses of Co-Lead Plaintiffs in the manner described in Section XIX below.
6. If you are a Class Member, you may, but are not required to, enter an appearance through counsel of your own choosing and at your own expense, provided that such counsel must file an appearance on your behalf on or before January 6, 2016, and must serve copies of such appearance on the attorneys listed in Section XIX below. If you do not enter an appearance through counsel of your own choosing, you will be represented by Lead Counsel: Robbins Geller Rudman & Dowd LLP, Robert M. Rothman, 58 South Service Road, Suite 200, Melville, New York 11747 and Labaton Sucharow LLP, Jonathan Gardner, 140 Broadway, 34th Floor, New York, New York 10005.

## **XIII. PLAN OF ALLOCATION**

The Net Settlement Fund will be distributed to Class Members who, in accordance with the terms of the Stipulation, are entitled to a distribution from the Net Settlement Fund pursuant to the Plan of Allocation or any order of the Court and who submit a valid and timely Proof of Claim under the Plan of Allocation described below. The Plan of Allocation provides that you will be eligible to participate in the distribution of the Net Settlement Fund only if you have an overall net loss on all of your transactions in CVS Caremark common stock during the Class Period.

For purposes of formulating the Plan of Allocation and determining the amount an Authorized Claimant may recover under it, Lead Counsel have conferred with their damages expert regarding the Plan of Allocation and it reflects an assessment of the damages that they believe could have been recovered by Class Members had Co-Lead Plaintiffs prevailed at trial.

In the unlikely event there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant's claim, as defined below. If, however, and as is more likely, the amount in the Net Settlement Fund is not sufficient to permit payment of the total claim of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant's claim bears to the total of the claims of all Authorized Claimants. Payment in this manner shall be deemed conclusive against all Authorized Claimants.

The allocation below for common stock is based on market adjusted price declines as well as the statutory PSLRA 90-day look-back amount.

The calculation of claims below is not an estimate of the amount you will receive. It is a formula for allocating the Net Settlement Fund among all Authorized Claimants. To the extent that a calculation results in a negative number, that number shall be set to zero.

A claim will be calculated as follows:

For each share of CVS common stock purchased or otherwise acquired during the Class Period, and:

- (a) sold within the Class Period, the claim per share is zero.
- (b) sold on November 5, 2009, the claim per share is the lesser of:
  - (i) \$5.44; or
  - (ii) the difference between the purchase price per share and the sales price per share.
- (c) retained beyond November 5, 2009 but sold on or before February 2, 2010, the claim per share is the least of:
  - (i) \$5.44; or
  - (ii) the difference between the purchase price per share and the sales price per share; or

- (d) retained beyond February 2, 2010, the claim per share is the lesser of:
- (i) \$5.44; or
  - (ii) the difference between the purchase price per share and \$31.93 per share.

**Table-1: Average Closing Prices for the 90 Days After the Class Period**

Sale Date	Closing Price Per Share	Average Closing Price Per Share
11/5/2009	\$28.87	\$28.87
11/6/2009	\$29.79	\$29.33
11/9/2009	\$30.90	\$29.85
11/10/2009	\$29.86	\$29.86
11/11/2009	\$30.00	\$29.88
11/12/2009	\$29.67	\$29.85
11/13/2009	\$30.25	\$29.91
11/16/2009	\$30.19	\$29.94
11/17/2009	\$30.44	\$30.00
11/18/2009	\$30.69	\$30.07
11/19/2009	\$31.08	\$30.16
11/20/2009	\$31.64	\$30.28
11/23/2009	\$31.89	\$30.41
11/24/2009	\$31.60	\$30.49
11/25/2009	\$31.53	\$30.56
11/27/2009	\$31.20	\$30.60
11/30/2009	\$31.01	\$30.62
12/1/2009	\$31.18	\$30.66
12/2/2009	\$31.11	\$30.68
12/3/2009	\$30.80	\$30.69
12/4/2009	\$30.76	\$30.69
12/7/2009	\$30.85	\$30.70
12/8/2009	\$30.56	\$30.69
12/9/2009	\$31.03	\$30.70
12/10/2009	\$31.50	\$30.74
12/11/2009	\$32.22	\$30.79
12/14/2009	\$32.36	\$30.85
12/15/2009	\$31.76	\$30.88
12/16/2009	\$30.93	\$30.89
12/17/2009	\$31.20	\$30.90

Sale Date	Closing Price Per Share	Average Closing Price Per Share
12/18/2009	\$31.18	\$30.90
12/21/2009	\$32.30	\$30.95
12/22/2009	\$32.31	\$30.99
12/23/2009	\$32.09	\$31.02
12/24/2009	\$32.14	\$31.05
12/28/2009	\$32.39	\$31.09
12/29/2009	\$32.65	\$31.13
12/30/2009	\$32.71	\$31.17
12/31/2009	\$32.21	\$31.20
1/4/2010	\$32.98	\$31.25
1/5/2010	\$32.85	\$31.28
1/6/2010	\$32.56	\$31.32
1/7/2010	\$33.76	\$31.37
1/8/2010	\$34.00	\$31.43
1/11/2010	\$33.93	\$31.49
1/12/2010	\$33.56	\$31.53
1/13/2010	\$33.97	\$31.58
1/14/2010	\$33.95	\$31.63
1/15/2010	\$33.91	\$31.68
1/19/2010	\$33.95	\$31.73
1/20/2010	\$33.85	\$31.77
1/21/2010	\$33.24	\$31.80
1/22/2010	\$33.24	\$31.82
1/25/2010	\$33.04	\$31.85
1/26/2010	\$32.81	\$31.86
1/27/2010	\$32.47	\$31.87
1/28/2010	\$32.33	\$31.88
1/29/2010	\$32.37	\$31.89
2/1/2010	\$32.92	\$31.91
2/2/2010	\$33.38	\$31.93

The date of purchase or sale is the “contract” or “trade” date as distinguished from the “settlement” date.

For Class Members who held CVS Caremark common stock at the beginning of the Class Period or made multiple purchases, acquisitions, or sales during the Class Period, the First-In, First-Out (“FIFO”) method will be applied to such holdings, purchases, acquisitions, and sales for purposes of calculating a claim. Under the FIFO method, sales of CVS Caremark common stock during the Class Period will be matched, in chronological order, first against shares of common stock held at the beginning of the Class Period. The remaining sales of common stock during the Class Period will then be matched, in chronological order, against common stock purchased or acquired during the Class Period. No claim per share will be calculated for any purchase of CVS Caremark common stock to cover a short sale.

A Class Member will be eligible to receive a distribution from the Net Settlement Fund only if a Class Member had a net overall loss, after all profits from transactions in all CVS Caremark common stock described above during the Class Period are subtracted from all losses. However, the proceeds from sales of common stock that have been matched against the common stock held at the beginning of the Class Period will not be used in the calculation of such net loss. No distributions will be made to Authorized Claimants who would otherwise receive a distribution of less than \$10.00.

The Court has reserved jurisdiction to allow, disallow, or adjust the claim of any Class Member on equitable grounds.

<sup>1</sup> Pursuant to Section 21D(e)(1) of the PSLRA, “in any private action arising under this chapter in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market.” \$31.93 was the mean (average) daily closing trading price of CVS common stock during the 90-day period beginning on November 5, 2009 and ending on February 2, 2010.

Case 1:09-cv-00554-JWL-PAS Document 135-1 Filed 12/15/15 Page 8 of 15 PageID #: 3842  
Payment shall be made to the Net Settlement Fund for the benefit of all Class Members, including the Effective Date, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. No Person shall have any claim against Co-Lead Plaintiffs, Co-Lead Plaintiffs' counsel, the Claims Administrator, or any other Person designated by Lead Counsel, Defendants, or Defendants' counsel based on distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. All Class Members who fail to complete and submit a valid and timely Proof of Claim shall be barred from participating in distributions from the Net Settlement Fund (unless otherwise ordered by the Court), but otherwise shall be bound by all of the terms of the Stipulation, including the terms of any judgment entered and the releases given.

#### **XIV. PARTICIPATION IN THE SETTLEMENT**

**TO PARTICIPATE IN THE DISTRIBUTION OF THE NET SETTLEMENT FUND, YOU MUST TIMELY SUBMIT A PROOF OF CLAIM.** A Proof of Claim is enclosed with this Notice or it may be downloaded at [www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com). Read the instructions carefully, fill out the Proof of Claim, include all the documents the form asks for, sign it, and mail or submit it online so that it is **postmarked or received no later than March 23, 2016**. The claim form may be submitted online at [www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com). Unless the Court orders otherwise, if you do not timely submit a valid Proof of Claim, you will be barred from receiving any payments from the Net Settlement Fund, but will in all other respects be bound by the provisions of the Stipulation and the Judgment.

#### **XV. EXCLUSION FROM THE CLASS**

You may request to be excluded from the Class. To do so, you must mail a written request stating that you wish to be excluded from the Class to:

*CVS Caremark Litigation*  
EXCLUSIONS  
c/o A.B. Data, Ltd.  
3410 West Hopkins Street  
P.O. Box 170500  
Milwaukee, WI 53217

The request for exclusion must include: (1) your name, address, and telephone number; (2) a list of all purchases, acquisitions, and sales of CVS Caremark common stock made from October 30, 2008 through November 4, 2009, inclusive, including the dates and prices of each purchase, acquisition, or sale, and the number of shares purchased, acquired, or sold; and (3) a statement that you wish to be excluded from the Class. **YOUR EXCLUSION REQUEST MUST BE POSTMARKED ON OR BEFORE JANUARY 6, 2016.** If you submit a valid and timely request for exclusion, you shall have no rights under this Settlement, shall not share in the distribution of the Net Settlement Fund, and shall not be bound by the Stipulation or the Judgment.

#### **XVI. DISMISSAL AND RELEASES**

If the proposed Settlement is approved, the Court will enter the Judgment. Upon the Effective Date, Co-Lead Plaintiffs and each of the Class Members, for themselves and for any other Person claiming (now or in the future) through or on behalf of them, and regardless of whether any such plaintiff or Class Member ever seeks or obtains by any means, including, without limitation, by submitting a Proof of Claim, any distribution from the Settlement Fund, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged all Released Claims against the Released Persons, and shall be permanently barred and enjoined from instituting, commencing, or prosecuting any such Released Claim against the Released Persons except to enforce the releases and other terms and conditions contained in the Stipulation or the Judgment entered pursuant thereto. In addition, upon the Effective Date, each of the Released Persons shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged Co-Lead Plaintiffs, each and all of the Class Members, and Co-Lead Plaintiffs' counsel from all claims and causes of action of every nature and description (including Unknown Claims), whether arising under federal, state, common or foreign law, that arise out of or relate in any way to the institution, prosecution, or settlement of the claims against Defendants ("Released Defendants' Claims"), except for claims relating to the enforcement of the Settlement.

#### **XVII. APPLICATION FOR FEES AND EXPENSES**

At the Settlement Hearing, Lead Counsel will request the Court to award attorneys' fees of up to 30% of the Settlement Amount, plus expenses not to exceed \$1,050,000.00, plus interest thereon. In addition, each of the three Co-Lead Plaintiffs may seek up to \$20,000 in expenses (including lost wages) they incurred in representing the Class. Such sums as may be approved by the Court will be paid from the Settlement Fund. Class Members are not personally liable for any such fees or expenses.

To date, Lead Counsel have not received any payment for their services in conducting this Litigation on behalf of Co-Lead Plaintiffs and the Class, nor have counsel been paid their expenses. The fee requested by Lead Counsel will compensate counsel for their efforts in achieving the Settlement for the benefit of the Class, and for their risk in undertaking this representation on a wholly-contingent basis. Lead Counsel believe that the fee requested is well within the range of fees awarded to plaintiffs' counsel under similar circumstances in other litigation of this type. The fee to be requested has been approved by Co-Lead Plaintiffs.

#### **XVIII. CONDITIONS FOR SETTLEMENT**

The Settlement is conditioned upon the occurrence of certain events described in the Stipulation. Those events include, among other things: (1) entry of the Judgment by the Court, as provided for in the Stipulation; and (2) expiration of the time to appeal from the Judgment or to move to alter or amend the Judgment, or the determination of any such appeal or motion in a manner to permit the consummation of the Settlement substantially as provided for in the Stipulation. If, for any reason, any one of the conditions described in the Stipulation is not met, the

**XIX. THE RIGHT TO OBJECT AND BE HEARD AT THE SETTLEMENT HEARING**

Any Class Member who objects to any aspect of the Settlement, the Plan of Allocation, the application for attorneys' fees and expenses, or the expenses of Co-Lead Plaintiffs may appear and be heard at the Settlement Hearing. However, any such Person must submit a written notice of objection, such that it is **received on or before January 6, 2016**, by each of the following:

TO THE COURT:	TO LEAD COUNSEL:	TO COUNSEL FOR CERTAIN DEFENDANTS:
CLERK OF THE COURT UNITED STATES DISTRICT COURT DISTRICT OF RHODE ISLAND Federal Building and Courthouse One Exchange Terrace Providence, RI 02903	ROBBINS GELLER RUDMAN & DOWD LLP ROBERT M. ROTHMAN 58 South Service Road, Suite 200 Melville, NY 11747 -and- LABATON SUCHAROW LLP JONATHAN GARDNER 140 Broadway, 34th Floor New York, NY 10005	WILLIAMS & CONNOLLY LLP STEVEN M. FARINA 725 Twelfth Street, N.W. Washington, D.C. 20005

The notice of objection must include the objecting Person's name, address, and telephone number; must demonstrate the objecting Person's membership in the Class, including the number of shares of CVS Caremark common stock purchased, acquired, and sold during the Class Period; and must contain a statement of the reasons for objection. Only Members of the Class who have submitted written notices of objection in this manner will be entitled to be heard at the Settlement Hearing, unless the Court orders otherwise.

**XX. SPECIAL NOTICE TO NOMINEES**

Nominees who purchased or acquired the common stock of CVS Caremark for the beneficial interest of other Persons during the Class Period shall, within ten (10) calendar days after receipt of this Notice: (1) provide the Claims Administrator with the names and addresses of such beneficial owners to: *CVS Caremark Litigation*, Attn: Fulfillment Department, c/o A.B. Data, Ltd., 3410 West Hopkins Street, P.O. Box 170200, Milwaukee, WI 53217; or (2) forward a copy of this Notice and the Proof of Claim by First-Class Mail to each such beneficial owner and, provide Lead Counsel with written confirmation that the Notice and Proof of Claim have been so forwarded. Upon submission of appropriate documentation, Lead Counsel will reimburse your reasonable costs and expenses of complying with this provision. Additional copies of this Notice may be obtained from the Claims Administrator by writing to:

*CVS Caremark Litigation*  
Claims Administrator  
c/o A.B. Data, Ltd.  
P.O. Box 170200  
Milwaukee, WI 53217  
info@CVSSecuritiesSettlement.com

**XXI. EXAMINATION OF PAPERS**

This Notice contains only a summary of the terms of the proposed Settlement and does not describe all of the details of the Stipulation. For a more detailed statement of the matters involved in the Litigation, reference is made to the pleadings, to the Stipulation, and to other papers filed in the Litigation, which may be inspected at the office of the Clerk of the Court, United States District Court for the District of Rhode Island, Federal Building and Courthouse, One Exchange Terrace, Providence, RI 02903. In addition, certain settlement related documents, including the Stipulation, may be viewed at [www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com).

If you have any questions about the Settlement, you may contact Lead Counsel by writing to:

ROBBINS GELLER RUDMAN  
& DOWD LLP  
ROBERT M. ROTHMAN  
58 South Service Road, Suite 200  
Melville, NY 11747

LABATON SUCHAROW LLP  
JONATHAN GARDNER  
140 Broadway, 34th Floor  
New York, NY 10005

**DO NOT TELEPHONE THE COURT REGARDING THIS NOTICE.**

DATED: November 20, 2015

BY ORDER OF THE COURT  
UNITED STATES DISTRICT COURT  
DISTRICT OF RHODE ISLAND



RICHARD MEDOFF, Individually and On )  
Behalf Of All Others Similarly Situated, )  
)  
Plaintiff, )  
)  
vs. )  
)  
CVS CAREMARK CORPORATION, et al., )  
)  
Defendants. )  
)

No. 1:09-cv-00554-JNL-PAS  
CLASS ACTION

**PROOF OF CLAIM AND RELEASE**

**I. GENERAL INSTRUCTIONS**

1. To recover as a Member of the Class based on your claims in the action entitled *Richard Medoff v. CVS Caremark Corporation, et al.*, No. 1:09-cv-00554-JNL-PAS (D.R.I.) (the “Litigation”), you must complete and, on page 6 hereof, sign this Proof of Claim and Release form. If you fail to submit a timely and properly addressed (as set forth in paragraph 3 below) Proof of Claim and Release form, your claim may be rejected and you may not receive any recovery from the Net Settlement Fund created in connection with the proposed Settlement.
2. Submission of this Proof of Claim and Release form, however, does not assure that you will share in the proceeds of the Settlement of the Litigation.
3. **YOU MUST MAIL OR SUBMIT ONLINE YOUR COMPLETED AND SIGNED PROOF OF CLAIM AND RELEASE FORM, ACCOMPANIED BY COPIES OF THE DOCUMENTS REQUESTED HEREIN, NO LATER THAN MARCH 23, 2016, ADDRESSED AS FOLLOWS:**

*CVS Caremark Litigation*  
Claims Administrator  
c/o A.B. Data, Ltd.  
P.O. Box 170200  
Milwaukee, WI 52317  
[www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com)

If you are NOT a Member of the Class (as defined in the Notice of Proposed Settlement of Class Action (“Notice”)) DO NOT submit a Proof of Claim and Release form.

4. If you are a Member of the Class and you did not timely request exclusion, you are bound by the terms of any judgment entered in the Litigation, including the releases provided therein, WHETHER OR NOT YOU SUBMIT A PROOF OF CLAIM AND RELEASE FORM.

**II. CLAIMANT IDENTIFICATION**

If you purchased or acquired CVS Caremark common stock and held the certificate(s) in your name, you are the beneficial purchaser or acquirer as well as the record purchaser or acquirer. If, however, you purchased or acquired CVS Caremark common stock and the certificate(s) were registered in the name of a third party, such as a nominee or brokerage firm, you are the beneficial purchaser or acquirer and the third party is the record purchaser or acquirer.

Case 1:09-cv-00554-JNL-PAS Document 135-1 Filed 12/15/15 Page 11 of 15 PageID #: 3845  
Use Part I of this form entitled "Claimant Identification" to identify each purchaser or acquirer of stock ("purchaser" if different from the beneficial purchaser or acquirer of the CVS Caremark common stock that forms the basis of this claim. THIS CLAIM MUST BE FILED BY THE ACTUAL BENEFICIAL PURCHASER(S) OR ACQUIRER(S) OR THE LEGAL REPRESENTATIVE OF SUCH PURCHASER(S) OR ACQUIRER(S) OF THE CVS CAREMARK COMMON STOCK UPON WHICH THIS CLAIM IS BASED.

All joint purchasers or acquirers must sign this claim. Executors, administrators, guardians, conservators, and trustees must complete and sign this claim on behalf of persons represented by them and their authority must accompany this claim and their titles or capacities must be stated. The Social Security (or taxpayer identification) number and telephone number of the beneficial owner may be used in verifying the claim. Failure to provide the foregoing information could delay verification of your claim or result in rejection of the claim.

### III. CLAIM FORM

Use Part II of this form entitled "Schedule of Transactions in CVS Caremark Common Stock" to supply all required details of your transaction(s) in CVS Caremark common stock. If you need more space or additional schedules, attach separate sheets giving all of the required information in substantially the same form. Sign and print or type your name on each additional sheet.

On the schedules, provide all of the requested information with respect to **all** of your purchases/acquisitions and **all** of your sales of CVS Caremark common stock which took place during the period October 30, 2008 through and including February 2, 2010, whether such transactions resulted in a profit or a loss. You must also provide all of the requested information with respect to **all** of the shares of CVS Caremark common stock you held at the close of trading on October 29, 2008 and February 2, 2010. Failure to report all such transactions may result in the rejection of your claim.

List each transaction separately and in chronological order, by trade date, beginning with the earliest. You must accurately provide the month, day, and year of each transaction you list.

The date of covering a "short sale" is deemed to be the date of purchase of CVS Caremark common stock. The date of a "short sale" is deemed to be the date of sale of CVS Caremark common stock.

Copies of broker confirmations or other documentation of your transactions in CVS Caremark common stock should be attached to your claim. Failure to provide this documentation could delay verification of your claim or result in rejection of your claim.

NOTICE REGARDING ELECTRONIC FILES: Certain claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. This is different from the online submission process that is available at [www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com). If you have a large number of transactions and wish to file your claim electronically, you must contact the Claims Administrator at [info@CVSSecuritiesSettlement.com](mailto:info@CVSSecuritiesSettlement.com) or 800-949-0206 to obtain the required file layout.

For Official Use Only  


DO NOT BE POSTMARKED OR  
RECEIVED NO LATER THAN  
MARCH 23, 2016

**PROOF OF CLAIM AND RELEASE FORM**  
PLEASE TYPE OR PRINT

**PART I—CLAIMANT IDENTIFICATION**

Beneficial Owner's Name (First, Middle, Last)

Joint Beneficial Owner's Name (First, Middle, Last)

Company/Trust/Other Entity (If Claimant Is Not an Individual)      Contact Person (If Claimant Is Not an Individual)

Trustee/Nominee/Other

Account Number (If Claimant Is Not an Individual)      Trust Date/Other (If Applicable)

Address Line 1

Address Line 2 (If Applicable)

City      State      Zip Code

Foreign Province      Foreign Postal Code      Foreign Country

Social Security Number      Taxpayer Identification Number  
OR

- Check Appropriate box:
- Individual or Sole Proprietor
  - Corporation
  - IRA
  - Partnership
  - Pension Plan
  - Trust
  - Estate
  - Other (please specify)

Telephone Number (Daytime)      Telephone Number (Evening)

Email Address (Email address is not required, but if you provide it you authorize the Claims Administrator to use it in providing you with information relevant to this claim.)

Failure to provide proof of all holdings, purchases, acquisitions, and sales information requested below will impede proper processing of your claim and may result in the rejection of your claim. Please include proper documentation with your Proof of Claim and Release form as described in detail in Section III above.

<b>1. BEGINNING HOLDINGS</b> —State the total number of shares of CVS Caremark common stock held as of the close of trading on October 29, 2008. If none, write “0” or “Zero.” (Must be documented.)				Proof Enclosed <input type="radio"/> Y <input type="radio"/> N
<b>2. PURCHASES/ACQUISITIONS DURING THE CLASS PERIOD AND 90-DAY LOOK-BACK PERIOD</b> —Separately list each and every purchase/acquisition <sup>1</sup> of CVS Caremark common stock from October 30, 2008 through and including the close of trading on February 2, 2010. (Must be documented.) <sup>2</sup>				
Date of Purchase (List Chronologically) (Month/Day/Year)	Number of Shares Purchased	Purchase Price Per Share	Total Purchase Price (excluding taxes, commissions and fees)	Proof Enclosed
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
<b>3. SALES DURING THE CLASS PERIOD AND 90-DAY LOOK-BACK PERIOD</b> —Separately list each and every sale/disposition of CVS Caremark common stock from October 30, 2008 through and including the close of trading on February 2, 2010. (Must be documented.)				
Date of Sale (List Chronologically) (Month/Day/Year)	Number of Shares Sold	Sale Price Per Share	Total Sale Price (excluding taxes, commissions and fees)	Proof Enclosed
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
/ /		\$	\$	<input type="radio"/> Y <input type="radio"/> N
<b>4. ENDING HOLDINGS</b> —State the total number of shares of CVS Caremark common stock held as of the close of trading on February 2, 2010. If none, write “0” or “Zero.” (Must be documented.)				Proof Enclosed <input type="radio"/> Y <input type="radio"/> N

<sup>1</sup> If you received shares through an acquisition or merger, please identify the date, the share amount, and the company acquired.

<sup>2</sup> If any purchase listed covered a “short sale,” please mark Yes.  Yes

#### IV. SUBMISSION TO JURISDICTION OF COURT AND ACKNOWLEDGMENTS

I (We) submit this Proof of Claim and Release under the terms of the Stipulation of Settlement described in the Notice. I (We) also submit to the jurisdiction of the United States District Court for the District of Rhode Island, with respect to my (our) claim as a Class Member and for purposes of enforcing the release set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in the Litigation. I (We) agree to furnish additional information to the Claims Administrator to support this claim (including transactions in other CVS Caremark securities) if requested to do so. I (We) have not submitted any other claim covering the same purchases, acquisitions, or sales of CVS Caremark common stock during the Class Period and know of no other person having done so on my (our) behalf.

#### V. RELEASE

1. Upon the Effective Date of the Settlement, I (we) acknowledge full and complete satisfaction of, and fully, finally, and forever settle, release, and discharge from the Released Claims each and all of the “Released Persons,” defined as each and all of the Defendants and their Related Parties. “Related Parties” means each of a Defendant’s respective present and former parents, subsidiaries, divisions and affiliates and the respective present and former employees, members, partners, principals, officers, directors, attorneys, advisors, accountants, auditors, and insurers of each of them; and the predecessors, successors, estates, heirs, executors, trusts, trustees, administrators, agents, representatives and assigns of each of them, in their capacity as such.

2. “Released Claims” means any and all claims and causes of action of every nature and description, whether known or unknown, whether arising under federal, state, common or foreign law, that arise out of or relate in any way to both: (i) the purchase or acquisition of CVS Caremark common stock during the Class Period, and (ii) the acts, facts, statements, or omissions that were asserted or could have been asserted in the Litigation by Co-Lead Plaintiffs or Members of the Class. “Released Claims” does not include: (i) claims to enforce the Settlement; and (ii) claims in any related derivative action. “Released Claims” includes “Unknown Claims” as defined below.

3. “Unknown Claims” means any Released Claims or Released Defendants’ Claims which any of the Settling Parties or Class Members do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, Co-Lead Plaintiffs, plaintiffs’ counsel, or Class Members which, if known by him, her, or it, might have affected his, her, or its settlement with and release, or might have affected his, her, or its decision not to object to this Settlement or release of the Released Persons, Co-Lead Plaintiffs, plaintiffs’ counsel, or Class Members. With respect to any and all Released Claims and Released Defendants’ Claims, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each of the Settling Parties shall be deemed to have, and by operation of the Judgment shall have, expressly waived the provisions, rights, and benefits of California Civil Code §1542, which provides:

**A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.**

The Settling Parties shall expressly waive and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable or equivalent to California Civil Code §1542. The Settling Parties may hereafter discover facts in addition to or different from those which he, she, or it now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants’ Claims, but the Settling Parties shall expressly settle and release and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims and Released Defendants’ Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and a key element of the Settlement of which this release is a part.

4. I (We) hereby warrant and represent that I (we) have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any matter released pursuant to this release or any other part or portion thereof.

5. I (We) hereby warrant and represent that I (we) have included the information requested about all of my (our) transactions in CVS Caremark common stock which are the subject of this claim, which occurred between October 30, 2008 and February 2, 2010, inclusive, as well as the opening and closing positions in such securities held by me (us) on the dates requested in this claim form.

I declare under penalty of perjury under the laws of the United States of America that all of the foregoing information supplied on this Proof of Claim and Release form by the undersigned is true and correct.

Executed this \_\_\_\_\_ day of \_\_\_\_\_, in \_\_\_\_\_, \_\_\_\_\_.  
(Month / Year) (City) (State / Country)

(Sign your name here)

(Type or print your name here)

(Capacity of person(s) signing, e.g., Beneficial Purchaser/Acquirer, Executor or Administrator)

**ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME.  
THANK YOU FOR YOUR PATIENCE.**

Reminder Checklist:

- 1. Please sign the above release and declaration.
- 2. If this claim is being made on behalf of Joint Claimants, then both must sign.
- 3. Remember to attach copies of supporting documentation, if available.
- 4. **Do not send** originals of certificates.
- 5. Keep a copy of your claim form and all supporting documentation for your records.
- 6. If you desire an acknowledgment of receipt of your claim form, please send it Certified Mail, Return Receipt Requested.
- 7. If you move, please send your new address to the address below.
- 8. **Do not use red pen or highlighter** on the Proof of Claim and Release form or supporting documentation.

**THIS PROOF OF CLAIM AND RELEASE MUST BE SUBMITTED ONLINE OR MAILED NO LATER THAN MARCH 23, 2016,  
ADDRESSED AS FOLLOWS:**

*CVS Caremark Litigation*  
Claims Administrator  
c/o A.B. Data, Ltd.  
P.O. Box 170200  
Milwaukee, WI 52317  
[www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com)

# EXHIBIT B

UNITED STATES DISTRICT COURT DISTRICT OF RHODE ISLAND

RICHARD MEDOFF, Individually and On Behalf of All Others Similarly Situated, Plaintiff, vs. CVS CAREMARK CORPORATION, et al., Defendants.

No. 1:09-cv-00554-JNL-PAS

CLASS ACTION

SUMMARY NOTICE

TO: ALL PERSONS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE COMMON STOCK OF CVS CAREMARK CORPORATION ("CVS CAREMARK") (N/K/A CVS HEALTH CORPORATION) DURING THE PERIOD OCTOBER 30, 2008 THROUGH NOVEMBER 4, 2009, INCLUSIVE, AND WERE DAMAGED THEREBY YOU ARE HEREBY NOTIFIED, pursuant to an Order of the United States District Court for the District of Rhode Island, that a hearing will be held on January 19, 2016, at 10:00 a.m., before the Honorable Joseph N. Laplante, United States District Judge, at the United States District Court for the District of New Hampshire, 55 Pleasant Street, Courtroom 2, Concord, New Hampshire 03301-3941, for the purpose of determining: (1) whether the proposed Settlement of the claims in the Litigation for the principal amount of \$48,000,000.00, plus interest, should be approved by the Court as fair, reasonable, and adequate; (2) whether a Final Judgment and Order of Dismissal with Prejudice should be entered by the Court dismissing the Litigation with prejudice; (3) whether the Plan of Allocation of Settlement proceeds is fair, reasonable, and adequate and should be approved; and (4) whether the application of Lead Counsel for the payment of attorneys' fees and expenses and Co-Lead Plaintiffs' expenses in connection with this Litigation should be approved.

IF YOU PURCHASED, OR OTHERWISE ACQUIRED, THE COMMON STOCK OF CVS CAREMARK DURING THE PERIOD OCTOBER 30, 2008 THROUGH NOVEMBER 4, 2009, INCLUSIVE, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION. If you have not received a detailed Notice of Proposed Settlement of Class Action ("Notice") and a copy of the Proof of Claim and Release form, you may obtain copies by writing to CVS Caremark Litigation, Claims Administrator, c/o A.B. Data, Ltd., P.O. Box 170200, Milwaukee, WI 53217 or on the internet at www.CVSSecuritiesSettlement.com. If you are a Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release by mail or online no later than March 23, 2016, establishing that you are entitled to recovery. You will be bound by any judgment rendered in the Litigation unless you request to be excluded, in writing, to the above address, postmarked on or before January 6, 2016. Any objection to the Settlement, the Plan of Allocation of Settlement proceeds, or the fee and expense application must be received, not simply postmarked, by each of the following recipients no later than January 6, 2016:

CLERK OF THE COURT UNITED STATES DISTRICT COURT DISTRICT OF RHODE ISLAND Federal Building and Courthouse One Exchange Terrace Providence, RI 02903

Lead Counsel: ROBBINS GELLER RUDMAN & DOWD LLP ROBERT M. ROTHMAN 58 South Service Road, Suite 200 Melville, NY 11747

LABATON SUCHAROW LLP JONATHAN GARDNER 140 Broadway, 34th Floor New York, NY 10005

Counsel for Certain Defendants: WILLIAMS & CONNOLLY LLP STEVEN M. FARINA 725 Twelfth Street, N.W. Washington, D.C. 20005

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE. If you have any questions about the Settlement, you may contact Lead Counsel at the addresses listed above.

DATED: December 4, 2015

BY ORDER OF THE COURT UNITED STATES DISTRICT COURT DISTRICT OF RHODE ISLAND

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-SmCapHndx, A-SmI Growr, A-SmI Val, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include C-MutlStvs, E-StratIncom, Frank/Tmp FrAd, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-GrowOppor, A-Health, A-MidCap, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-SmI Growr, A-SmI Val, A-SmI Div, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include B-Value, A-Value, A-Value, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Advconsumer, A-AllSecEqF, A-AllSecEqF, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-HealthCare, A-Technology, FidelityAdvFoc, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.

Table with 4 columns: 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg], and 36 Mos Performance Rating, 4Wk Net % Asset NAV [Chg|Value|Chg]. Rows include A-Health, A-Health, A-Health, etc.



# EXHIBIT C



(<http://www.prnewswire.com/>)

 **PRINT THIS**

## Robbins Geller Rudman & Dowd LLP And Labaton Sucharow LLP Announce Summary Notice In The Case Entitled Richard Medoff v. CVS Caremark Corporation, et al., No. 1:09-cv-00554-JNL-PAS (D.R.I)

NEW YORK, Dec. 4, 2015 /PRNewswire/ -- TO: ALL PERSONS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE COMMON STOCK OF CVS CAREMARK CORPORATION ("CVS CAREMARK") (N/K/A CVS HEALTH CORPORATION) DURING THE PERIOD OCTOBER 30, 2008 THROUGH NOVEMBER 4, 2009, INCLUSIVE, AND WERE DAMAGED THEREBY

YOU ARE HEREBY NOTIFIED, pursuant to an Order of the United States District Court for the District of Rhode Island, that a hearing will be held on January 19, 2016, at 10:00 a.m., before the Honorable Joseph N. Laplante, United States District Judge, at the United States District Court for the District of New Hampshire, 55 Pleasant Street, Courtroom 2, Concord, New Hampshire 03301-3941, for the purpose of determining: (1) whether the proposed Settlement of the claims in the Litigation for the principal amount of \$48,000,000.00, plus interest, should be approved by the Court as fair, reasonable, and adequate; (2) whether a Final Judgment and Order of Dismissal with Prejudice should be entered by the Court dismissing the Litigation with prejudice; (3) whether the Plan of Allocation of Settlement proceeds is fair, reasonable, and adequate and should be approved; and (4) whether the application of Lead Counsel for the payment of attorneys' fees and expenses and Co-Lead Plaintiffs' expenses in connection with this Litigation should be approved.

IF YOU PURCHASED, OR OTHERWISE ACQUIRED, THE COMMON STOCK OF CVS CAREMARK DURING THE PERIOD OCTOBER 30, 2008 THROUGH NOVEMBER 4, 2009, INCLUSIVE, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION. If you have not received a detailed Notice of Proposed Settlement of Class Action ("Notice") and a copy of the Proof of Claim and Release form, you may obtain copies by writing to *CVS Caremark Litigation*, Claims Administrator, c/o A.B. Data, Ltd., P.O. Box 170200, Milwaukee, WI 53217 or on the internet at [www.CVSSecuritiesSettlement.com](http://www.CVSSecuritiesSettlement.com) (<http://www.CVSSecuritiesSettlement.com>). If you are a Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release by mail or online **no later than March 23, 2016**, establishing that you are entitled to recovery. You will be bound by any judgment rendered in the Litigation unless you request to be excluded, in writing, to the above address, **postmarked on or before January 6, 2016**.

Any objection to the Settlement, the Plan of Allocation of Settlement proceeds, or the fee and expense application must be **received**, not simply postmarked, by each of the following recipients **no later than January 6, 2016**:

CLERK OF THE COURT  
UNITED STATES DISTRICT COURT  
DISTRICT OF RHODE ISLAND  
Federal Building and Courthouse  
One Exchange Terrace  
Providence, RI 02903

***Lead Counsel:***

ROBBINS GELLER RUDMAN  
& DOWD LLP  
ROBERT M. ROTHMAN  
58 South Service Road, Suite 200  
Melville, NY 11747

LABATON SUCHAROW LLP  
JONATHAN GARDNER  
140 Broadway, 34th Floor  
New York, NY 10005

***Counsel for Certain Defendants:***

WILLIAMS & CONNOLLY LLP  
STEVEN M. FARINA  
725 Twelfth Street, N.W.  
Washington, D.C. 20005

**PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE.** If you have any questions about the Settlement, you may contact Lead Counsel at the addresses listed above.

DATED: December 4, 2015

BY ORDER OF THE COURT  
UNITED STATES DISTRICT COURT  
DISTRICT OF RHODE ISLAND

SOURCE Robbins Geller Rudman & Dowd LLP and Labaton Sucharow LLP

RELATED LINKS

<http://www.cvssecuritiessettlement.com> (<http://www.cvssecuritiessettlement.com>)

**Find this article at:**

[http://www.prnewswire.com/news-releases/robbins-geller-rudman--dowd-llp-and-labaton-sucharow-llp-announce-summary-notice-in-the-case-entitled-richard-medoff-v-cvs-caremark-corporation-et-al-no-109-cv-00554-jnl-pas-dri-300188322.html?tc=eml\\_cleartime](http://www.prnewswire.com/news-releases/robbins-geller-rudman--dowd-llp-and-labaton-sucharow-llp-announce-summary-notice-in-the-case-entitled-richard-medoff-v-cvs-caremark-corporation-et-al-no-109-cv-00554-jnl-pas-dri-300188322.html?tc=eml_cleartime)

Check the box to include the list of links referenced in the article.